Catherine Sebban

8.8k citations

92 papers · 5.5k indexed · 2 hit papers · h-index 36

Impact in

Pathology and Forensic Medicine top 0.1%
- Lymphoma Diagnosis and Treatment
Genetics top 0.5%
- Chronic Lymphocytic Leukemia Research

Papers in

Pathology and Forensic Medicine 52
- Lymphoma Diagnosis and Treatment 52
Genetics 30
- Chronic Lymphocytic Leukemia Research 23

Co-authors: Bertrand Coiffier Éric Lepage Gilles Salles Christian Gisselbrecht Hervé Tilly André Bosly Jean‐Yves Blay Philippe Gaulard
Journals: Blood (26 papers)Journal of Clinical Oncology (16 papers)Cancer (5 papers)Annals of Oncology (5 papers)Leukemia (3 papers)
Partner nations: France Belgium United States

In The Last Decade

Catherine Sebban

88 papers receiving 5.4k citations

Hit Papers

align trajectories log scale

Lymphopenia as a Prognostic Factor for Overall Survival in Advanced Carcinomas, Sarcomas, and Lymphomas 2009 · 624 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2009 Cancer Research
2005 Journal of Clinical Oncology

Peers

Countries citing papers authored by Catherine Sebban

Since Specialization

Citations

This map shows the geographic impact of Catherine Sebban's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Catherine Sebban with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Catherine Sebban more than expected).

Fields of papers citing papers by Catherine Sebban

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Catherine Sebban. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Catherine Sebban. The network helps show where Catherine Sebban may publish in the future.

Co-authors

The 25 scholars most cited alongside Catherine Sebban, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Catherine Sebban Line = papers co-authored together Catherine Sebban links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Addition of Rituximab to Chlorambucil Produces Superior Event-Free Survival in the Treatment of Patients With Extranodal Marginal-Zone B-Cell Lymphoma: 5-Year Analysis of the IELSG-19 Randomized Study Journal of Clinical Oncology ·Emanuele Zucca, Annarita Conconi, Daniele Laszlò, Armando López‐Guillermo, Réda Bouabdallah, Bertrand Coiffier, Catherine Sebban, Fabrice Jardin, Umberto Vitolo, Franck Morschhauser, Stefano Pileri, Christiane Copie‐Bergman, Elı́as Campo, Andrew Jack, Irene Floriani, Peter Johnson, Maurizio Martelli, Franco Cavalli, Giovanni Martinelli, Catherine Thiéblemont	2013	148
2	Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma Haematologica ·Emmanuel Bachy, Roch Houot, F. Morschhauser, Anne Sonet, Pauline Brice, Karim Belhadj, Guillaume Cartron, B. Audhuy, Christophe Fermé, Pierre Feugier, Catherine Sebban, Vincent Delwail, Hervé Maisonneuve, Steven Le Gouill, Sophie Lefort, Nicole Brousse, C. Foussard, Gilles Salles, (unknown)	2013	60
3	Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up Annals of Oncology ·P Colombat, Nicole Brousse, Gilles Salles, Franck Morschhauser, Pauline Brice, Pierre Soubeyran, Vincent Delwail, Éric Deconinck, Corinne Haïoun, C. Foussard, Catherine Sebban, H. Tilly, Catherine Thiéblemont, Laurence Bergougnoux, F. Lazreg, P. Solal-Céligny	2012	36
4	Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor? Blood ·Hervé Avet‐Loiseau, Florent Malard, L. Campion, Florence Magrangeas, Catherine Sebban, Bruno Lioure, Olivier Decaux, Thierry Lamy, Laurence Legros, Jean‐Gabriel Fuzibet, Mauricette Michallet, Bernadette Corront, Pascal Lenain, Cyrille Hulin, Claire Mathiot, Michel Attal, Thierry Façon, Jean‐Luc Harousseau, Stéphane Minvielle, Philippe Moreau, (unknown)	2010	92
5	Lymphoma Recurrence 5 Years or Later Following Diffuse Large B-Cell Lymphoma: Clinical Characteristics and Outcome Journal of Clinical Oncology ·Jean-François Larouche, Françoise Berger, Catherine Chassagne‐Clément, Martine Ffrench, Evelyne Callet‐Bauchu, Catherine Sebban, Hervé Ghesquières, Florence Broussais‐Guillaumot, Gilles Salles, Bertrand Coiffier	2010	92
6	90yttrium Ibritumomab Tiuxetan (zevalin) Combined With Beam (z-beam) Conditioning Regimen Plus Autologous Stem Cell Transplantation in Relapsed Or Refractory Follicular Lymphoma. a Gela Phase Ii Prospective Study Digital Access to Libraries ·Christian Gisselbrecht, Didier Decaudin, Nicolas Mounier, Hervé Tilly, Vincent Ribrag, Catherine Sebban, Nöel Milpied, Franck Morschhauser, Bertrand Coiffier, Steven Le Gouill, P Lederlin, Richard Delarue, G. Laurent, André Bosly	2009	1
7	Long-term follow-up of an age-adapted C5R protocol followed by radiotherapy in 99 newly diagnosed primary CNS lymphomas: a prospective multicentric phase II study of the Groupe d’Etude des Lymphomes de l’Adulte (GELA) Annals of Oncology ·Hervé Ghesquières, Céline Ferlay, Catherine Sebban, David Pérol, André Bosly, Olivier Casasnovas, Oumédaly Reman, Bertrand Coiffier, Hervé Tilly, Pierre Morel, Éric Van Den Neste, Philippe Colin, Corinne Haïoun, Pierre Biron, Jean‐Yves Blay	2009	49
8	Risk-Adapted Salvage Treatment With Single or Tandem Autologous Stem-Cell Transplantation for First Relapse/Refractory Hodgkin's Lymphoma: Results of the Prospective Multicenter H96 Trial by the GELA/SFGM Study Group Journal of Clinical Oncology ·Franck Morschhauser, Pauline Brice, Christophe Fermé, Marine Diviné, Gilles Salles, Réda Bouabdallah, Catherine Sebban, Laurent Voillat, Olivier Casasnovas, Aspasia Stamatoullas, Krimo Bouabdallah, Marc André, Jean-Philippe Jaı̈s, Dominique Cazals‐Hatem, Christian Gisselbrecht	2008	90
9	CD4 lymphopenia as a risk factor for febrile neutropenia and early death after cytotoxic chemotherapy in adult patients with cancer Cancer ·Christophe Borg, Isabelle Ray‐Coquard, Irène Philip, Gilles Clapisson, Nathalie Bendriss‐Vermare, Christine Ménétrier‐Caux, Catherine Sebban, Pierre Biron, Jean‐Yves Blay	2004	73
10	Smoking and non-Hodgkin's lymphoma: a case–control study in the Rhône-Alpes region of France Cancer Causes & Control ·Hervé Besson, P. Renaudier, Ray M. Merrill, Bertrand Coiffier, Catherine Sebban, J. Fabry, Christian Trépo, Annie J. Sasco	2003	22
11	Involved field irradiation (IFRT) does not improve outcome in patients with stage III/IV Hodgkin's lymphoma (HL) in complete remission after MOPP/ABV (M/A): Results of the randomised EORTC trial 20884 Blood ·Jmm Raemaekers, Berthe M.P. Aleman, M. Henry‐Amar, Umberto Tirelli, Anton Hagenbeek, Patrice Carde, W Peters, Radka Tomšič, A Van Hoof, M. van ‘t Veer, José Thomas, W Schroyens, Hanneke C. Kluin‐Nelemans, Catherine Sebban, Dominique Bron, Houchingue Eghbali, A. Pinna, Mandard Am	2001	6
12	Rituximab plus CHOP (R-CHOP) in the treatment of elderly patients with diffuse large B-cell lymphoma. An update of the GELA study. Blood ·Bertrand Coiffier, C. Fermé, Olivier Hermine, Corinne Haïoun, E Baumelou, P. Solal-Céligny, Alain Delmer, Catherine Sebban, Nicolas Mounier, G. Tertian, Ambro van Hoof, André Bosly	2001	5
13	Research controversies in management of oral mucositis Supportive Care in Cancer ·Pierre Biron, Catherine Sebban, R. Gourmet, Gisèle Chvetzoff, I Philip, Jean‐Yves Blay	2000	42
14	Late intensification is superior to early intensification in relapsing/refractory aggressive non-Hodgkin's lymphoma. A randomized study from the GELA: LNH RP93. Experimental Hematology ·André Bosly, Anne Sonet, Gilles Salles, P. Brice, Corinne Haïoun, Y Kerneis, Hervé Tilly, P Lederlin, Isabelle Plantier, Catherine Sebban, Bertrand Coiffier	1997	1
15	Age-adapted induction treatment of acute lymphoblastic leukemia in the elderly and assessment of maintenance with interferon combined with chemotherapy. A multicentric prospective study in forty patients Leukemia ·André Delannoy, Catherine Sebban, Pascale Cony‐Makhoul, Bruno Cazin, Catherine Cordonnier, Réda Bouabdallah, J Cahn, François Dreyfus, Alain Sadoun, Vernant Jp, Caroline Gay, A Broustet, Jl. Michaux, D Fière	1997	25
16	Design and validation of a bedside decision instrument to elicit a patient's preference concerning allogenic bone marrow transplantation in chronic myeloid leukemia American Journal of Hematology ·Catherine Sebban, George P. Browman, Amiram Gafni, Gail A. Van Norman, Mark N. Levine, David Assouline, D Fière	1995	47
17	Chemotherapy combined with zidovudine and GM-CSF in human immunodeficiency virus-related non-Hodgkin's lymphoma Annals of Oncology ·Jean Gabarre, Éric Lepage, A. Thyss, R. Tubiana, Y Bastion, D Schlaifer, Catherine Sebban, Vincent Ribrag, M. Fereres, Martine Raphaël, (unknown)	1995	17
18	Maintenance with low-dose cytarabine for acute myeloid leukemia in complete remission Annals of Hematology ·E Archimbaud, Bruno Anglaret, Xavier Thomas, J Jaubert, Catherine Sebban, Denis Guyotat, D Fière	1992	6
19	Treatment of low‐grade non‐Hodgkin's lymphomas: Assessment of doxorubicin in a controlled trial Hematological Oncology ·Éric Lepage, Catherine Sebban, C Gisselbrecht, Bertrand Coiffier, Jean‐Luc Harousseau, P.A. Bryon, M Boiron	1990	35
20	Phase II trial of plicamycin and hydroxyurea in acute myelogenous leukemia Cancer Chemotherapy and Pharmacology ·E Archimbaud, Jacques Troncy, Catherine Sebban, Denis Guyotat, Yves Devaux, Martine French, Michel Moriceau, Jean‐Jacques Viala, D Fière	1989	9

About Catherine Sebban

Catherine Sebban is a scholar working on Pathology and Forensic Medicine, Genetics, Hematology, Oncology and Neurology, having authored 92 papers that have together received 5.5k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (52 papers), Chronic Lymphocytic Leukemia Research (23 papers), Acute Lymphoblastic Leukemia research (19 papers), Acute Myeloid Leukemia Research (14 papers), Viral-associated cancers and disorders (14 papers), CNS Lymphoma Diagnosis and Treatment (14 papers), Neutropenia and Cancer Infections (13 papers) and Lung Cancer Treatments and Mutations (11 papers). The work is most often cited by research in Pathology and Forensic Medicine (3.3k citations), Genetics (1.4k citations), Oncology (3.0k citations), Hematology (1.1k citations) and Neurology (1.1k citations). Catherine Sebban has collaborated with scholars based in France, Belgium and United States. Frequent co-authors include Bertrand Coiffier, Éric Lepage, Gilles Salles, Christian Gisselbrecht, Hervé Tilly, André Bosly, Jean‐Yves Blay, Philippe Gaulard, Pierre Biron and Franck Morschhauser. Their work appears in journals such as Blood, Journal of Clinical Oncology, Cancer, Annals of Oncology and Leukemia.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact